Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen V Liu

Showing results (141-150 of 187) with videos related to

Pageof 19
Sort By:
Frontiers in Oncology|May 11, 2023
<i>ERBB</i> family fusions are recurrent and actionable oncogenic targets across cancer typesLaura Schubert, Andrew Elliott, Anh T Le, et al.
The New England Journal of Medicine|October 4, 2018
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Aaron S Mansfield, Aleksandra Szczęsna, et al.
JTO Clinical and Research Reports|June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLCAlexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2020
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumorsKhanh T Do, Geraldine O'Sullivan Coyne, John L Hays, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2018
ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic EventsTerry L Ng, Derek E Smith, Rao Mushtaq, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2015
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung CancerAnna F Farago, Long P Le, Zongli Zheng, et al.
Nature Cancer|March 26, 2024
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancersMaishara Muquith, Magdalena Espinoza, Andrew Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2023
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung CancerCharles M Rudin, Stephen V Liu, Ross A Soo, et al.
The Oncologist|July 10, 2024
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumorsDan Morgenstern-Kaplan, Samuel A Kareff, Asaad Trabolsi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2021
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung CancerRafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, et al.
Pageof 19

Showing results (141-150 of 187) with videos related to

Sort By:
Pageof 19
Frontiers in Oncology|May 11, 2023
<i>ERBB</i> family fusions are recurrent and actionable oncogenic targets across cancer typesLaura Schubert, Andrew Elliott, Anh T Le, et al.
The New England Journal of Medicine|October 4, 2018
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Aaron S Mansfield, Aleksandra Szczęsna, et al.
JTO Clinical and Research Reports|June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLCAlexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2020
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumorsKhanh T Do, Geraldine O'Sullivan Coyne, John L Hays, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2018
ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic EventsTerry L Ng, Derek E Smith, Rao Mushtaq, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2015
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung CancerAnna F Farago, Long P Le, Zongli Zheng, et al.
Nature Cancer|March 26, 2024
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancersMaishara Muquith, Magdalena Espinoza, Andrew Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2023
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung CancerCharles M Rudin, Stephen V Liu, Ross A Soo, et al.
The Oncologist|July 10, 2024
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumorsDan Morgenstern-Kaplan, Samuel A Kareff, Asaad Trabolsi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2021
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung CancerRafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, et al.
Pageof 19